Akten is owned by Akorn.
Akten contains Lidocaine Hydrochloride.
Akten has a total of 1 drug patent out of which 0 drug patents have expired.
Akten was authorised for market use on 07 October, 2008.
Akten is available in gel;ophthalmic dosage forms.
Akten can be used as method of inducing topical anesthesia in the eye.
The generics of Akten are possible to be released after 24 July, 2026.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8759401 | AKORN | Aqueous gel formulation and method for inducing topical anesthesia |
Jul, 2026
(3 years from now) |
Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 October, 2008
Treatment: Method of inducing topical anesthesia in the eye
Dosage: GEL;OPHTHALMIC
7
United States
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic